Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 08, 2023 16:11 ET
|
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
November 02, 2023 10:37 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 30, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
October 26, 2023 15:19 ET
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for...
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
October 23, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
October 19, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
October 16, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
October 13, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL...
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
September 18, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 16, 2023 10:56 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...